JP2008063295A - Skin care preparation containing platinum/silver colloid - Google Patents
Skin care preparation containing platinum/silver colloid Download PDFInfo
- Publication number
- JP2008063295A JP2008063295A JP2006244674A JP2006244674A JP2008063295A JP 2008063295 A JP2008063295 A JP 2008063295A JP 2006244674 A JP2006244674 A JP 2006244674A JP 2006244674 A JP2006244674 A JP 2006244674A JP 2008063295 A JP2008063295 A JP 2008063295A
- Authority
- JP
- Japan
- Prior art keywords
- skin
- platinum
- silver
- colloid
- solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 title claims abstract description 125
- 229910052697 platinum Inorganic materials 0.000 title claims abstract description 63
- 239000000084 colloidal system Substances 0.000 title claims abstract description 51
- 239000004332 silver Substances 0.000 title claims abstract description 32
- 229910052709 silver Inorganic materials 0.000 title claims abstract description 32
- 238000002360 preparation method Methods 0.000 title claims abstract description 22
- 239000007788 liquid Substances 0.000 claims abstract description 14
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 claims description 34
- 230000003078 antioxidant effect Effects 0.000 claims description 15
- 239000002537 cosmetic Substances 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 10
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 6
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 claims description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 4
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 claims description 4
- 102000008186 Collagen Human genes 0.000 claims description 3
- 108010035532 Collagen Proteins 0.000 claims description 3
- 229920001436 collagen Polymers 0.000 claims description 3
- 229940114496 olive leaf extract Drugs 0.000 claims description 3
- 239000011732 tocopherol Substances 0.000 claims description 3
- 229930003799 tocopherol Natural products 0.000 claims description 3
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 claims description 2
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 claims description 2
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 claims description 2
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 claims description 2
- 229960000458 allantoin Drugs 0.000 claims description 2
- 235000017471 coenzyme Q10 Nutrition 0.000 claims description 2
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 claims description 2
- 229940110767 coenzyme Q10 Drugs 0.000 claims description 2
- 229960003720 enoxolone Drugs 0.000 claims description 2
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 claims description 2
- 239000001685 glycyrrhizic acid Substances 0.000 claims description 2
- 229960004949 glycyrrhizic acid Drugs 0.000 claims description 2
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 claims description 2
- 235000019410 glycyrrhizin Nutrition 0.000 claims description 2
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims description 2
- 229920002674 hyaluronan Polymers 0.000 claims description 2
- 239000000419 plant extract Substances 0.000 claims description 2
- 229960001295 tocopherol Drugs 0.000 claims description 2
- 235000010384 tocopherol Nutrition 0.000 claims description 2
- 230000000699 topical effect Effects 0.000 claims description 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims description 2
- 229920001287 Chondroitin sulfate Polymers 0.000 claims 1
- 235000004347 Perilla Nutrition 0.000 claims 1
- 244000124853 Perilla frutescens Species 0.000 claims 1
- 229940107200 chondroitin sulfates Drugs 0.000 claims 1
- 239000000284 extract Substances 0.000 claims 1
- 150000004492 retinoid derivatives Chemical class 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 8
- 230000001603 reducing effect Effects 0.000 abstract description 5
- 230000003064 anti-oxidating effect Effects 0.000 abstract description 4
- 230000003647 oxidation Effects 0.000 abstract description 4
- 238000007254 oxidation reaction Methods 0.000 abstract description 4
- 201000004624 Dermatitis Diseases 0.000 abstract description 3
- 208000010201 Exanthema Diseases 0.000 abstract description 3
- 206010061218 Inflammation Diseases 0.000 abstract description 3
- 206010042496 Sunburn Diseases 0.000 abstract description 3
- 230000032683 aging Effects 0.000 abstract description 3
- 230000002421 anti-septic effect Effects 0.000 abstract description 3
- 201000005884 exanthem Diseases 0.000 abstract description 3
- 230000004054 inflammatory process Effects 0.000 abstract description 3
- 230000000813 microbial effect Effects 0.000 abstract description 3
- 230000019612 pigmentation Effects 0.000 abstract description 3
- 206010037844 rash Diseases 0.000 abstract description 3
- 239000004599 antimicrobial Substances 0.000 abstract 1
- 238000013329 compounding Methods 0.000 abstract 1
- 230000001747 exhibiting effect Effects 0.000 abstract 1
- 238000007788 roughening Methods 0.000 abstract 1
- 210000003491 skin Anatomy 0.000 description 32
- 230000000052 comparative effect Effects 0.000 description 15
- 239000000839 emulsion Substances 0.000 description 12
- 239000000243 solution Substances 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 239000006071 cream Substances 0.000 description 10
- 238000002156 mixing Methods 0.000 description 10
- 239000003963 antioxidant agent Substances 0.000 description 8
- 235000006708 antioxidants Nutrition 0.000 description 8
- 239000003921 oil Substances 0.000 description 6
- 239000002245 particle Substances 0.000 description 6
- 229910052751 metal Inorganic materials 0.000 description 5
- 239000002184 metal Substances 0.000 description 5
- 235000019198 oils Nutrition 0.000 description 5
- 229910052760 oxygen Inorganic materials 0.000 description 5
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 150000002500 ions Chemical class 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- -1 retinoids Substances 0.000 description 4
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 4
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000002105 nanoparticle Substances 0.000 description 3
- 230000001590 oxidative effect Effects 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-M L-ascorbate Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] CIWBSHSKHKDKBQ-JLAZNSOCSA-M 0.000 description 2
- 239000002211 L-ascorbic acid Substances 0.000 description 2
- 235000000069 L-ascorbic acid Nutrition 0.000 description 2
- 150000000996 L-ascorbic acids Chemical class 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 206010040880 Skin irritation Diseases 0.000 description 2
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000013065 commercial product Substances 0.000 description 2
- NOPFSRXAKWQILS-UHFFFAOYSA-N docosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCO NOPFSRXAKWQILS-UHFFFAOYSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000010419 fine particle Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- 239000010931 gold Substances 0.000 description 2
- 229910052737 gold Inorganic materials 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 2
- 238000010606 normalization Methods 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 238000006722 reduction reaction Methods 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 230000009759 skin aging Effects 0.000 description 2
- 230000036556 skin irritation Effects 0.000 description 2
- 231100000475 skin irritation Toxicity 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 239000001587 sorbitan monostearate Substances 0.000 description 2
- 235000011076 sorbitan monostearate Nutrition 0.000 description 2
- 229940035048 sorbitan monostearate Drugs 0.000 description 2
- 229940032094 squalane Drugs 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 1
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 1
- JPPRXACMNPYJNK-UHFFFAOYSA-N 1-docosoxydocosane Chemical compound CCCCCCCCCCCCCCCCCCCCCCOCCCCCCCCCCCCCCCCCCCCCC JPPRXACMNPYJNK-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical class CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 229920002567 Chondroitin Polymers 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 206010034972 Photosensitivity reaction Diseases 0.000 description 1
- 206010040914 Skin reaction Diseases 0.000 description 1
- 206010070835 Skin sensitisation Diseases 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 231100000460 acute oral toxicity Toxicity 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 229940064004 antiseptic throat preparations Drugs 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- DLGJWSVWTWEWBJ-HGGSSLSASA-N chondroitin Chemical compound CC(O)=N[C@@H]1[C@H](O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@H](O)C=C(C(O)=O)O1 DLGJWSVWTWEWBJ-HGGSSLSASA-N 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 229960000735 docosanol Drugs 0.000 description 1
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000007760 free radical scavenging Effects 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 231100000017 mucous membrane irritation Toxicity 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 150000002948 pantothenic acids Chemical class 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 208000017983 photosensitivity disease Diseases 0.000 description 1
- 231100000434 photosensitization Toxicity 0.000 description 1
- 208000007578 phototoxic dermatitis Diseases 0.000 description 1
- 231100000018 phototoxicity Toxicity 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 150000003057 platinum Chemical class 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 231100000430 skin reaction Toxicity 0.000 description 1
- 230000035483 skin reaction Effects 0.000 description 1
- 231100000370 skin sensitisation Toxicity 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 235000019149 tocopherols Nutrition 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
- QUEDXNHFTDJVIY-UHFFFAOYSA-N γ-tocopherol Chemical class OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 QUEDXNHFTDJVIY-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Cosmetics (AREA)
Abstract
Description
本発明は各種成分による皮膚、頭皮および粘膜等への酸化作用を抑制し、尚且つ剤型自身の防腐効果を有する抗酸化性皮膚外用剤に関する。 The present invention relates to an anti-oxidative skin external preparation that suppresses the oxidative action of various components on the skin, scalp, mucous membrane, etc., and has the preservative effect of the dosage form itself.
生活環境の変化により人間は常に各種の酸化物質に曝されている。これら酸化物質に対処するため従来から使用されてきた抗酸化成分として、ビタミンＥ関連成分、β‐カロチン、コエンザイムＱ１０などの成分が提案されている。
また、最近では高活性の白金コロイドの有する電気二重層を皮膚に作用させることにより皮膚を保護し、皮膚の角質層の活性化が図られる白金ナノコロイド含有化粧料（特許文献１）が提案されている。この他、白金族金属と金とのコロイドを含む抗酸化剤からなる化粧料（特許文献２及び３）などにみられるように、金属コロイド、特に白金コロイドを配合した発明が出願されている。
このほか、銀ヒドロゾルを含有する化粧料（特許文献４）や超微粒子銀コロイドを含有する抗菌性の化粧料（特許文献５）などが提案されている。
Due to changes in the living environment, humans are constantly exposed to various oxidizing substances. As antioxidant components conventionally used to deal with these oxidizing substances, vitamin E related components, β-carotene, coenzyme Q10 and other components have been proposed.
Recently, a platinum nanocolloid-containing cosmetic (Patent Document 1) that protects the skin by causing an electric double layer of a highly active platinum colloid to act on the skin and activates the stratum corneum of the skin has been proposed. ing. In addition, as seen in cosmetics made of an antioxidant containing a colloid of platinum group metal and gold (Patent Documents 2 and 3), inventions in which metal colloids, particularly platinum colloids are blended have been filed.
In addition, cosmetics containing silver hydrosol (Patent Document 4) and antibacterial cosmetics containing ultrafine silver colloid (Patent Document 5) have been proposed.
しかしながら、化粧品に配合する抗酸化成分の配合や効果を考えた場合には、Ｌ‐アスコルビン酸塩およびＬ‐アスコルビン酸誘導体などは安定性に問題があり、しかも単回の還元作用によって、これ自身が酸化されるという問題点を有している。これに対して、ナノサイズの白金粒子は連続した抗酸化能を有していることと、表面での反応性が高く、高い触媒能があるために各種の活性酸素を消去できることなどの利点を有するが、コロイド化するため保護コロイド剤などによっては充分な効果が期待できない場合もあった。 However, L-ascorbate and L-ascorbic acid derivatives have problems in stability when considering the formulation and effects of antioxidant ingredients in cosmetics. Has the problem of being oxidized. On the other hand, nano-sized platinum particles have a continuous antioxidation ability and high surface reactivity and high catalytic ability, so that various active oxygen can be eliminated. However, since it colloids, there are cases where sufficient effects cannot be expected depending on the protective colloid agent.
本発明は老化肌の要因の一つとなる酸化を抑制する抗酸化性、すなわち還元能を有する成分を配合することにより皮膚の老化の予防および改善を目的としたものである。
この他、本発明は酸化によって発生するかぶれ、皮膚炎、肌荒れ、表皮保護、皮膚正常化、日焼け後の炎症や色素沈着等の軽減および修復効果はもとより、あえて防腐剤を含有させなくとも微生物防腐効果を有しており、一方、安全性についても優れた皮膚外用剤を提供することである。
更に本発明は、従来の白金、金、銀等の金属コロイドを成分とする化粧料の問題点を解決し、より優れた抗酸化活性を有する皮膚外用剤の提供を目的とするものである。
The object of the present invention is to prevent and improve skin aging by blending an antioxidant that suppresses oxidation, which is one of the factors of aging skin, that is, a component having a reducing ability.
In addition to the above, the present invention not only provides rash, dermatitis, rough skin, epidermal protection, normalization of skin, inflammation and pigmentation after sunburn, and mitigation and repair effects, but also microbial preservatives without any preservatives. On the other hand, it is to provide a skin external preparation excellent in safety.
Another object of the present invention is to solve the problems of conventional cosmetics containing metal colloids such as platinum, gold, and silver, and to provide a skin external preparation having superior antioxidant activity.
本発明者等は前記課題を解決するために、有効成分として白金コロイド液および白金／銀コロイド液を合わせ含有してなるものについて鋭意、検討した。その結果、白金コロイド液および白金／銀コロイド液を併用することにより、単独使用よりもより抗酸化作用が高く、しかも、これまで、必ず配合せざるを得なかった安全性に課題を残す防腐剤を配合する必要のない、皮膚化粧料としても使用できる皮膚外用剤を開発、完成するに至った。 In order to solve the above-mentioned problems, the present inventors diligently studied what contains a platinum colloid solution and a platinum / silver colloid solution as active ingredients. As a result, the combined use of a colloidal platinum solution and a colloidal platinum / silver solution has a higher anti-oxidation effect than a single use, and has left a problem in safety that has been inevitably required until now. Developed and completed a topical skin preparation that can be used as a skin cosmetic without the need for blending.
本発明は、ナノサイズの白金粒子の有する連続した抗酸化能、表面での高い反応性、高い触媒能による活性酸素消去能などに着目して白金コロイドを使用することにした。また、各種の白金コロイドの中でもゼータ電位があり、電子供与能がある白金ナノコロイドを使用した。
白金ナノコロイドは皮膚を透過しない特性があり、安全性の高い成分である。そこで、さらに安定性のある継続的抗酸化効果を向上させる目的で白金／銀コロイド液と併用することとした。白金／銀コロイド液は白金、銀、炭酸水素ナトリウム、セルロースガムと水とから構成されており、黄褐色の液体である。白金／銀コロイド液は、マイナスイオンを発生させることによって活性酸素を還元する作用を有している。さらにこれらの還元作用ばかりでなく、この白金／銀コロイド液は水分子と離れにくく、したがって皮膚への保湿性が保持されると同時に銀特有の殺菌防腐効果が得られるという複合効果も活用することが可能となる。
In the present invention, the colloidal platinum is used by paying attention to the continuous antioxidant ability of the nano-sized platinum particles, high reactivity on the surface, active oxygen scavenging ability due to high catalytic ability, and the like. In addition, among the various platinum colloids, platinum nanocolloids having zeta potential and electron donating ability were used.
Platinum nanocolloid has the property of not permeating the skin and is a highly safe component. Therefore, it was decided to use in combination with a platinum / silver colloidal solution for the purpose of improving the stable and continuous antioxidant effect. The platinum / silver colloid liquid is composed of platinum, silver, sodium hydrogen carbonate, cellulose gum and water, and is a yellowish brown liquid. The platinum / silver colloid liquid has an action of reducing active oxygen by generating negative ions. In addition to these reducing effects, this platinum / silver colloid solution is not easily separated from water molecules, and therefore, the combined effect of maintaining the moisture retention on the skin and at the same time providing the sterilization and antiseptic effect peculiar to silver should be utilized. Is possible.
本発明によれば老化肌の要因の一つとなる酸化を抑制する抗酸化性、すなわち還元能を有する成分、白金コロイド：白金／銀コロイドを配合することにより、皮膚の老化の予防および改善を達成することができる。この他、本発明は酸化によって発生するかぶれ、皮膚炎、肌荒れ等の予防ないし治癒、表皮保護、皮膚正常化、日焼け後の炎症や色素沈着等の軽減および修復効果はもとより、あえて防腐剤を含有させなくとも微生物防腐効果を有しており、一方、安全性にも優れた皮膚外用剤を得ることができる。 According to the present invention, prevention and improvement of skin aging can be achieved by blending a platinum colloid: platinum / silver colloid, an antioxidant that suppresses oxidation, which is one of the factors of aging skin, that is, a component having a reducing ability. can do. In addition, the present invention contains antiseptics as well as prevention and healing of rashes caused by oxidation, dermatitis, rough skin, epidermis protection, skin normalization, inflammation and pigmentation after sunburn, and reduction and repair effects. Even if it does not make it, it has a microbial preservative effect, On the other hand, the skin external preparation excellent in safety | security can be obtained.
以下、本発明について詳細に説明する。
白金コロイド液は金属塩還元反応法によって金属白金微粒子と水がひとつの粒子として構成されるように製造されたもので、その特性の一つとして白金コロイド粒子表面は高いゼータ電位を有していることがわかった。すなわち、水分子が白金微粒子周囲に集り、水分子に囲まれた白金粒子という形状を呈している。その結果、ナノ白金コロイドの表面は強力なマイナス（−）に荷電している。因みにフィーサー（株）製 エアーイオンカウンター FIC-2000によりマイナスイオンの発生量を、白金コロイド液を空中噴霧して測定したところ15,663個/ccであり、対照品としての水道水では12,738個/cc、また測定時の室内マイナスイオンは43個/ccであった。
Hereinafter, the present invention will be described in detail.
The platinum colloid liquid is manufactured by metal salt reduction reaction so that the metal platinum fine particles and water are composed as one particle, and one of the characteristics is that the surface of the platinum colloid particle has a high zeta potential. I understood it. That is, the water molecules gather around the platinum fine particles and form a shape of platinum particles surrounded by the water molecules. As a result, the surface of the nanoplatinum colloid is strongly negatively charged (-). By the way, the amount of negative ions generated by air ion counter FIC-2000 manufactured by Fieser Co., Ltd. was measured by spraying platinum colloidal liquid in the air, and it was 15,663 / cc, and 12,738 / cc in tap water as a control product, The indoor negative ions at the time of measurement were 43 / cc.
一方、白金／銀コロイド液は銀金属から直接法によって銀コロイドを得たものである。銀は優れた抗菌作用があり、抗菌剤、宇宙飛行士の飲料水の殺菌などに使用され、安全性の高いことも明らかになっている。
これらの成分は、皮膚外用剤に使用する際にはこれ自身の安定性や剤型中への配合性を良くする目的から上記で得た前者のナノ白金コロイドの他に適当な保護コロイド剤、例えばポリソルベート８０（Tween 80）と水が加えられている。後者の白金／銀コロイド液は、用途によって多少配合が異なるが、水約９９％、銀０．２％以下、炭酸水素ナトリウム０．１％以下、カルボキシメチルセルロース０．１％以下の構成になっており、ナノサイズの白金を４５０から５５０ppmの範囲で含んでいる。
なお、白金コロイド液も同様に使用目的によって異なるが、通常ナノサイズの白金を４００から６００ppmの範囲で含むものが使用される。
白金および銀のコロイドは、白金、銀とも、粒径１０ｎｍ以下、好ましくは５ｎｍ以下のものが使用できる。
On the other hand, the platinum / silver colloid solution is obtained by obtaining silver colloid from silver metal by a direct method. Silver has an excellent antibacterial effect, and it has been shown that it is highly safe because it is used for antibacterial agents, sterilization of astronaut drinking water, and so on.
These components are suitable protective colloids in addition to the former nanoplatinum colloids obtained above for the purpose of improving the stability of the ingredients themselves and the compoundability in the dosage form when used for external preparations for skin. For example, polysorbate 80 (Tween 80) and water are added. The latter platinum / silver colloidal liquid has a composition slightly different depending on the use, but is composed of about 99% water, 0.2% silver or less, 0.1% sodium bicarbonate or less, and 0.1% or less carboxymethylcellulose. And contains nano-sized platinum in the range of 450 to 550 ppm.
The colloidal platinum solution also varies depending on the purpose of use, but usually contains nanosized platinum in the range of 400 to 600 ppm.
As the colloid of platinum and silver, those having a particle diameter of 10 nm or less, preferably 5 nm or less can be used for both platinum and silver.
本発明の 皮膚外用剤に使用するナノ白金コロイドの好ましい配合量は０．１％から２．０％（重量）であり、より好ましい使用配合量は０．２％から１．０％である。皮膚外用剤への配合量が０．１％より少ないと抗酸化効果の発揮が充分でなく、２．０％以上の配合量では増加に見合うような著しい効果の増大は期待できないことから上記の含有量とした。
一方、白金／銀コロイド液の好ましい配合量は０．１％から２．０％であり、より好ましい使用配合量は０．２％から１．０％である。皮膚外用剤に対する含有量が０．１％より少ないと抗酸化効果を発揮することは困難であり、２．０％以上の含有量では見合うような著しい効果の増大は期待できない。
本発明の成分は化粧料、医薬品、医薬部外品など外皮に適用される皮膚外用剤として用いることができる。したがってその剤型として水溶性系（ローション系）、可溶化系、乳化系（Ｗ／Ｏ型、Ｏ／Ｗ型）、粉末系、軟膏系、油液系、ジェル系、水−油二層系、水−油−粉末三層系など幅広い形態に使用することができる。
A preferred blending amount of the nanoplatinum colloid used in the skin external preparation of the present invention is 0.1% to 2.0% (by weight), and a more preferred blending amount is 0.2% to 1.0%. If the blending amount in the external preparation for skin is less than 0.1%, the antioxidant effect is not sufficiently exerted, and if the blending amount is 2.0% or more, it is not possible to expect a significant increase corresponding to the increase. It was set as content.
On the other hand, a preferable blending amount of the platinum / silver colloidal solution is 0.1% to 2.0%, and a more preferable blending amount is 0.2% to 1.0%. If the content with respect to the external preparation for skin is less than 0.1%, it is difficult to exert an antioxidant effect, and if the content is 2.0% or more, a significant increase in the effect cannot be expected.
The component of the present invention can be used as a skin external preparation applied to the outer skin of cosmetics, pharmaceuticals, quasi drugs and the like. Therefore, as the dosage form, water-soluble (lotion), solubilization, emulsification (W / O, O / W), powder, ointment, oil / liquid, gel, water-oil two-layer system , Water-oil-powder three-layer system, etc.
本発明の皮膚外用剤は上記必須成分の他に皮膚外用剤に通常用いられる他の成分、例えば粉末、油分、湿潤剤、紫外線吸収剤、酸化防止剤、界面活性剤、防腐剤、ｐＨ調整剤、酵素、保湿剤、香料、水、多価アルコール、低級アルコール、高分子（増粘剤）、シリコーン類、色素などを必要に応じて適宜、配合することができる。
本発明の皮膚外用剤は必要によりさらに公知の薬剤を添加してもよい。これらの薬剤としては副腎皮質ホルモン類、レチノイド、トコフェロール、Ｌ‐アスコルビン酸塩およびＬ‐アスコルビン酸誘導体を含むビタミン類、アラントイン、グリチルリチン酸およびその誘導体、グリチレレチン酸およびその誘導体、ヒアルロン酸類およびコラーゲンやコンドロイチン硫酸塩類や植物抽出液、ビオチン、パントテン酸誘導体などがあげられる。
一方、白金コロイド液および白金／銀コロイド液の安全性については皮膚一次刺激性試験、皮膚感作性試験、急性経口毒性試験、眼粘膜刺激性試験、光毒性試験、光感作性試験、変異原性試験、環境試験およびヒトパッチテスト（皮膚貼付試験）を実施し、いずれも全く問題はなかった。
以下に実験例および実施例をあげて本発明について更に説明するが、本発明はこれら実施例に何ら限定するものではない。
In addition to the above essential components, the external preparation for skin of the present invention is other components usually used for external preparations for skin, such as powders, oils, wetting agents, UV absorbers, antioxidants, surfactants, preservatives, pH adjusters. , Enzymes, humectants, fragrances, water, polyhydric alcohols, lower alcohols, polymers (thickeners), silicones, pigments, and the like can be appropriately blended as necessary.
If necessary, the external preparation for skin of the present invention may further contain a known drug. These agents include corticosteroids, retinoids, tocopherols, vitamins including L-ascorbate and L-ascorbic acid derivatives, allantoin, glycyrrhizic acid and its derivatives, glycyrrhetinic acid and its derivatives, hyaluronic acids and collagen and chondroitin Examples thereof include sulfates, plant extracts, biotin, and pantothenic acid derivatives.
On the other hand, regarding the safety of platinum colloid liquid and platinum / silver colloid liquid, primary skin irritation test, skin sensitization test, acute oral toxicity test, ocular mucosal irritation test, phototoxicity test, photosensitization test, mutation A protogenicity test, an environmental test, and a human patch test (skin application test) were carried out, and there was no problem at all.
The present invention will be further described below with reference to experimental examples and examples, but the present invention is not limited to these examples.
実験例１（ナノ白金コロイド：白金／銀コロイド液による抗酸化能測定）
安定な有機ラジカルである1,1-diphenyl-2-picrylhydrazyl（ＤＰＰＨ）を消去する性質を指標にして抗酸化力を検討した（フリーラジカル消去活性測定法、化粧品の有用性／日本化粧品技術者会ならびに薬事日報社発行）。
試料はナノ白金コロイド：白金／銀コロイド液の比を５：１、２．５：１、１：１および０．５：１の割合で調製した各試験液の抗酸化性を測定した。
その結果、上記条件のどの割合においても抗酸化能を有することが判明した。
白金コロイド：白金／銀コロイド液ノ使用比は、５：１〜１：５の範囲で選択するとよい。
Experimental Example 1 (Nanoplatinum colloid: Antioxidation ability measurement with platinum / silver colloid solution)
Antioxidant activity was examined using the property of eliminating 1,1-diphenyl-2-picrylhydrazyl (DPPH), a stable organic radical, as an index (free radical scavenging activity measurement method, usefulness of cosmetics / Japan Cosmetic Engineers Association And published by Yakuji Nippo).
Samples were measured for the antioxidant properties of each test solution prepared at a ratio of nano-platinum colloid: platinum / silver colloid solution of 5: 1, 2.5: 1, 1: 1 and 0.5: 1.
As a result, it was found that it has antioxidant ability in any proportion of the above conditions.
The use ratio of platinum colloid: platinum / silver colloid liquid is preferably selected in the range of 5: 1 to 1: 5.
実験例２（使用試験）
１．試料の調製
以下に記載の実施例および比較例に使用するクリーム及び乳液を下記の組成にしたがって調製した。なお、％は重量％を示す。
〔クリーム組成物〕 実施例 比較例
（１）白金コロイド 0.2％ -
（２）白金／銀コロイド 1.0 -
（３）自己乳化型脂肪酸モノグリセライド 0.8 0.8
（４）ポリオキシエチレン(20E.O.)ソルビタン
モノステアレート 1.0 1.0
（５）セタノール 1.5 1.5
（６）ワセリン 3.5 3.5
（７）スクワラン 4.0 4.0
（８）グリセリン 6.0 6.0
（９）プロピレングリコール 1.0 1.0
（10）オリーブオイル 2.5 2.5
（11）カルボキシビニルポリマー 0.5 0.5
（12）水酸化カリウム 0.1 0.1
（13）天然ビタミンＥ 0.05 0.05
（14）オリーブ葉エキス 0.1 0.1
（15）水添レシチン 0.1 0.1
（16）香料 適量 適量
（17）精製水 100%になる残量 100%になる残量
（製法） 油相である(3),(4),(5),(6),(7),(10),(13),(15)を秤量し75℃に加温、混合し (8),(9),(12),(14),(17) を秤量し75℃に加温、混合して水相とする。水相、油相を混合,乳化して乳化物をつくり、その後冷却して35℃で(1),(2),(16)を加え,クリームとする。
得られた上記クリームを以下の実験例に使用した。
Experimental example 2 (use test)
1. Sample Preparation Creams and emulsions used in the examples and comparative examples described below were prepared according to the following composition. In addition,% shows weight%.
[Cream composition] Examples Comparative examples
(1) Platinum colloid 0.2%-
(2) Platinum / silver colloid 1.0-
(3) Self-emulsifying fatty acid monoglyceride 0.8 0.8
(4) Polyoxyethylene (20E.O.) sorbitan
Monostearate 1.0 1.0
(5) Cetanol 1.5 1.5
(6) Petrolatum 3.5 3.5
(7) Squalane 4.0 4.0
(8) Glycerin 6.0 6.0
(9) Propylene glycol 1.0 1.0
(10) Olive oil 2.5 2.5
(11) Carboxyvinyl polymer 0.5 0.5
(12) Potassium hydroxide 0.1 0.1
(13) Natural vitamin E 0.05 0.05
(14) Olive leaf extract 0.1 0.1
(15) Hydrogenated lecithin 0.1 0.1
(16) Fragrance Appropriate amount Appropriate amount (17) Purified water 100% remaining amount 100% remaining amount (method) (3), (4), (5), (6), (7), (10), (13), (15) are weighed and heated to 75 ° C and mixed. (8), (9), (12), (14), (17) are weighed and heated to 75 ° C. Mix to make aqueous phase. A water phase and an oil phase are mixed and emulsified to make an emulsion, then cooled and added with (1), (2), (16) at 35 ° C to make a cream.
The obtained cream was used in the following experimental examples.
つぎに示す処方および下記製法により乳液を得た。
〔乳液組成物〕 実施例 比較例
（１）ベヘニールアルコール 0.5 0.5
（２）合成ゲイロウ 2.0 2.0
（３）ソルビタンモノステアレート 1.2 1.2
（４）ポリオキシエチレン(20 E.O.)ベヘニールエーテル 1.8 1.8
（５）スクワラン 3.5 3.5
（６）ステアリン酸 0.9 0.9
（７）ブチレングリコール 9.0 9.0
（８）水酸化ナトリウム 0.1 0.1
（９）カルボニルビニルポリマー 0.1 0.1
（10）白金コロイド 1.0 -
（12）白金／銀コロイド 1.0 -
（13）オリーブ葉エキス 0.1 0.1
（14）加水分解コラーゲン 0.1 0.1
（15）トコフェロール 0.1 0.1
（16）精製水 100%とする適量 100%とする適量
（製法） 油相である(1),(2),(3),(4),(5),(6),(14)を秤量し、75℃に加温、混合し、水相である(7)(8),(9）,(12),(13),(15)を同様に秤量し、75℃に加温、混合した後、水相、油相を混合、乳化物を得た。その後冷却して35℃で(10),(11)を加えて乳液を調整する。
An emulsion was obtained by the following formulation and the following production method.
[Emulsion composition] Examples Comparative example (1) Behenyl alcohol 0.5 0.5
(2) Synthetic Gaylow 2.0 2.0
(3) Sorbitan monostearate 1.2 1.2
(4) Polyoxyethylene (20 EO) behenyl ether 1.8 1.8
(5) Squalane 3.5 3.5
(6) Stearic acid 0.9 0.9
(7) Butylene glycol 9.0 9.0
(8) Sodium hydroxide 0.1 0.1
(9) Carbonyl vinyl polymer 0.1 0.1
(10) Platinum colloid 1.0-
(12) Platinum / silver colloid 1.0-
(13) Olive leaf extract 0.1 0.1
(14) Hydrolyzed collagen 0.1 0.1
(15) Tocopherol 0.1 0.1
(16) Appropriate amount to make 100% purified water Appropriate amount to make 100% (Manufacturing method) The oil phase (1), (2), (3), (4), (5), (6), (14) Weigh and heat to 75 ° C, mix, weigh (7) (8), (9), (12), (13), (15) in the same way, and warm to 75 ° C, After mixing, an aqueous phase and an oil phase were mixed to obtain an emulsion. Then cool and add (10), (11) at 35 ° C to adjust the emulsion.
２．使用試験
実施例および比較例のクリームおよび乳液について、Ａ，Ｂ、Ｃグループとも２５才〜４２才の女子各８名づつを選び、各人の顔面を左右に分け、一方に実施例のクリームまたは乳液を、もう一方の顔面に比較例のクリームまたは乳液を毎日、朝晩、２回使用してもらい、７日後にアンケートを行って使用結果を調査した。
なお、比較例は実施例のクリームおよび乳液から、白金コロイドおよび／または白金／銀コロイドを除いたものを比較例とした。
比較例１：白金コロイドおよび白金／銀コロイドの両者を除いたもの、
比較例２：白金コロイドを除いたもの、
比較例３：白金／銀コロイドを除いたもの、
とした。グループＡ（実施例：比較例１）、Ｂ（実施例：比較例２）、Ｃ（実施例：比較例３）とした。
判定は以下の基準にしたがって使用感、肌の状態等について老化予防効果を含めて調査した。判定結果は各人の評価点数の合計点で示した。実施例の結果は、グループＡ＋Ｂ＋Ｃの合計値の１／３の数値を示す。
評価基準：
５ ： 非常に良い （肌荒れ等を全く生ぜず、肌の状態が非常に良い）
４ ： かなり良い （従来の市販品に比してより良好と感じる）
３ ： 良い （市販品と同程度）
２ ： 悪い （市販品より使用感等に劣る）
１ ： 非常に悪い （肌荒れを感じる）
2. Usage test For the creams and emulsions of the examples and comparative examples, select 8 girls each from age 25 to 42 in groups A, B and C, and divide each person's face into left and right, and the cream or The emulsion was used on the other face, and the comparative cream or emulsion was used twice daily, morning and evening, and a questionnaire was conducted 7 days later to investigate the results of use.
The comparative example was obtained by removing platinum colloid and / or platinum / silver colloid from the creams and emulsions of the examples.
Comparative Example 1: Excluding both platinum colloid and platinum / silver colloid,
Comparative Example 2: Excluding platinum colloid
Comparative Example 3: Excluding platinum / silver colloid
It was. Group A (Example: Comparative Example 1), B (Example: Comparative Example 2), and C (Example: Comparative Example 3).
Judgment was conducted according to the following criteria, including a feeling of use, skin condition, etc., including anti-aging effects. Judgment results are shown as the total score of each person. The result of an Example shows the numerical value of 1/3 of the total value of group A + B + C.
Evaluation criteria:
5: Very good (no rough skin, very good skin condition)
4: Pretty good (feels better than conventional products)
3: Good (same as commercial product)
2: Poor (Inferior to the commercial product, etc.)
1: Very bad (feels rough skin)
３．結果
クリーム組成物 乳液組成物
実施例 ４０ ３８
比較例１ ２２ ２３
比較例２ ２８ ３０
比較例３ ３０ ３４
なお、クリーム，乳液の両方とも実施例は皮膚のかぶれ等の副作用や使用者にとって好ましくない反応は全く観察されなかった。上記結果から、白金コロイドおよび白金／銀コロイドの両者を含む本発明品が良好な結果を示すことが理解できる。
3. result
Cream composition Emulsion composition
Example 40 38
Comparative Example 1 22 23
Comparative Example 2 28 30
Comparative Example 3 30 34
In both the cream and the emulsion, no side effects such as skin irritation and reactions unfavorable to the user were observed in the examples. From the above results, it can be understood that the product of the present invention containing both platinum colloid and platinum / silver colloid shows good results.
Claims (5)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2006244674A JP2008063295A (en) | 2006-09-08 | 2006-09-08 | Skin care preparation containing platinum/silver colloid |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2006244674A JP2008063295A (en) | 2006-09-08 | 2006-09-08 | Skin care preparation containing platinum/silver colloid |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2008063295A true JP2008063295A (en) | 2008-03-21 |
Family
ID=39286297
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006244674A Pending JP2008063295A (en) | 2006-09-08 | 2006-09-08 | Skin care preparation containing platinum/silver colloid |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP2008063295A (en) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009084243A (en) * | 2007-10-02 | 2009-04-23 | Pias Arise Kk | Horny layer hyaluronic acid production accelerator and external dermatological preparation, cosmetic, and quasi-drug containing horny layer hyaluronic acid production accelerator |
| WO2009104661A1 (en) * | 2008-02-20 | 2009-08-27 | パナソニック電工株式会社 | Antioxidant agent |
| JP2012031086A (en) * | 2010-07-29 | 2012-02-16 | Toyo Shinyaku Co Ltd | Antioxidant and cosmetic material |
| FR2985662A1 (en) * | 2012-01-16 | 2013-07-19 | Argentum Holding Sarl | DERMO-COSMETIC COMPOSITIONS BASED ON A SYNERGISTIC COLLOIDAL SILVER AND DESOXYRIBONUCLEIC ACID ASSOCIATION |
| KR101793266B1 (en) * | 2017-08-11 | 2017-11-02 | 주식회사 아리바이오 | The natural preservative manufacturing method of using Mandarin and Natural mineral |
| JP2020059706A (en) * | 2018-10-05 | 2020-04-16 | 大阪ガスケミカル株式会社 | Cosmetic composition and method for producing the same, and cosmetics |
| JP2021169422A (en) * | 2020-04-15 | 2021-10-28 | 大阪ガスケミカル株式会社 | Anti-inflammatory agent |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001002550A (en) * | 1999-06-18 | 2001-01-09 | Ichimaru Pharcos Co Ltd | Olive leaf extract, application to skin preparation for external use or bathing agent |
| JP2001026518A (en) * | 1999-07-13 | 2001-01-30 | Dhc Co | Preparation composition for external use for skin |
| JP2001122723A (en) * | 1999-10-27 | 2001-05-08 | I Betsukusu:Kk | Cosmetics |
| JP2004161632A (en) * | 2002-11-11 | 2004-06-10 | Daiwa Fine Chemicals Co Ltd (Laboratory) | Antibacterial, bactericidal or antifungal silver colloid composition and product utilizing the composition |
| JP2004231534A (en) * | 2003-01-28 | 2004-08-19 | Yasushi Kijima | Antibacterial cosmetic containing ultra fine silver particle colloid |
| WO2005018598A1 (en) * | 2003-08-22 | 2005-03-03 | Kose Corporation | Agent for eliminating singlet oxygen and composition using the same |
| JP2005139102A (en) * | 2003-11-05 | 2005-06-02 | Shetech:Kk | Platinum nanocolloid-containing cosmetic |
| JP2006160650A (en) * | 2004-12-06 | 2006-06-22 | Asahi Kasei Chemicals Corp | Anti-aging cosmetic |
-
2006
- 2006-09-08 JP JP2006244674A patent/JP2008063295A/en active Pending
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001002550A (en) * | 1999-06-18 | 2001-01-09 | Ichimaru Pharcos Co Ltd | Olive leaf extract, application to skin preparation for external use or bathing agent |
| JP2001026518A (en) * | 1999-07-13 | 2001-01-30 | Dhc Co | Preparation composition for external use for skin |
| JP2001122723A (en) * | 1999-10-27 | 2001-05-08 | I Betsukusu:Kk | Cosmetics |
| JP2004161632A (en) * | 2002-11-11 | 2004-06-10 | Daiwa Fine Chemicals Co Ltd (Laboratory) | Antibacterial, bactericidal or antifungal silver colloid composition and product utilizing the composition |
| JP2004231534A (en) * | 2003-01-28 | 2004-08-19 | Yasushi Kijima | Antibacterial cosmetic containing ultra fine silver particle colloid |
| WO2005018598A1 (en) * | 2003-08-22 | 2005-03-03 | Kose Corporation | Agent for eliminating singlet oxygen and composition using the same |
| JP2005139102A (en) * | 2003-11-05 | 2005-06-02 | Shetech:Kk | Platinum nanocolloid-containing cosmetic |
| JP2006160650A (en) * | 2004-12-06 | 2006-06-22 | Asahi Kasei Chemicals Corp | Anti-aging cosmetic |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009084243A (en) * | 2007-10-02 | 2009-04-23 | Pias Arise Kk | Horny layer hyaluronic acid production accelerator and external dermatological preparation, cosmetic, and quasi-drug containing horny layer hyaluronic acid production accelerator |
| WO2009104661A1 (en) * | 2008-02-20 | 2009-08-27 | パナソニック電工株式会社 | Antioxidant agent |
| JP2012031086A (en) * | 2010-07-29 | 2012-02-16 | Toyo Shinyaku Co Ltd | Antioxidant and cosmetic material |
| FR2985662A1 (en) * | 2012-01-16 | 2013-07-19 | Argentum Holding Sarl | DERMO-COSMETIC COMPOSITIONS BASED ON A SYNERGISTIC COLLOIDAL SILVER AND DESOXYRIBONUCLEIC ACID ASSOCIATION |
| WO2013107687A3 (en) * | 2012-01-16 | 2014-04-03 | ARGENTUM Holding S à.r.l. | Dermocosmetic compositions based on a synergistic combination of colloidal silver and deoxyribonucleic acid |
| KR101793266B1 (en) * | 2017-08-11 | 2017-11-02 | 주식회사 아리바이오 | The natural preservative manufacturing method of using Mandarin and Natural mineral |
| JP2020059706A (en) * | 2018-10-05 | 2020-04-16 | 大阪ガスケミカル株式会社 | Cosmetic composition and method for producing the same, and cosmetics |
| JP7341834B2 (en) | 2018-10-05 | 2023-09-11 | 大阪ガスケミカル株式会社 | Cosmetic composition and its manufacturing method, and cosmetics |
| JP2021169422A (en) * | 2020-04-15 | 2021-10-28 | 大阪ガスケミカル株式会社 | Anti-inflammatory agent |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101987903B1 (en) | Cosmetic composition for treating atopic dermatitis and method thereof | |
| US20150110724A1 (en) | High SPF Transparent or Translucent Naturally Derived, Cytoprotective, UV Radiation Resistant Compositions | |
| JP2008063295A (en) | Skin care preparation containing platinum/silver colloid | |
| CN108125803A (en) | A kind of whitening spot-eliminating composition | |
| KR102142311B1 (en) | Skin external composition comprising tangeretin | |
| CN107137243A (en) | Anti-acne facial treatment milk and preparation method thereof | |
| EP3589279A1 (en) | Skin treatment methods and compositions with retinoid and delivery systems thereof | |
| JP2005306850A (en) | Antidermopathic agent and skin lotion containing the same | |
| JP2007332078A (en) | Agent for external use containing ozone-dissolved glycerol solution such as cosmetic, quasi-drug or medicament (pharmaceutical) | |
| JPH07101844A (en) | Multilayered emulsion | |
| CN107028797A (en) | Anti-acne essence and preparation method thereof | |
| JP2004175750A (en) | Dermopathy inhibitor and dermopathy improving agent, and skin care preparation for external use containing them | |
| JP2008273922A (en) | External preparation for skin and external preparation for mucosa | |
| JPWO2007135841A1 (en) | Cosmetics containing dimer dilinoleic acid diethylene glycol oligomer ester | |
| CN107595662B (en) | Synergistic compositions, formulations and related methods for reducing ultraviolet-induced lipid peroxidation | |
| CN108186496A (en) | A kind of skin whitening, moisturizing skin care item | |
| JP2676049B2 (en) | Skin cosmetics | |
| JP2009001575A (en) | Agent for external use containing ozone-dissolved glycerol solution such as cosmetic, quasi-drug or medicament (pharmaceutical) | |
| JP3119622B2 (en) | Cosmetics | |
| KR102233710B1 (en) | Cosmetic composition containing salt and manufacturing method thereof | |
| JP4880233B2 (en) | Anti-dermatological agent and external preparation for skin containing the same | |
| JPH08104635A (en) | External pharmaceutical preparation containing zinc phytate as active ingredient | |
| JP5233149B2 (en) | Adapalene-containing external preparation composition | |
| JP4933768B2 (en) | Anti-dermatological agent and external preparation for skin containing the same | |
| JP2982872B1 (en) | External preparation for slimming skin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20090820 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20110426 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110706 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20120125 |